Cyramza indication extended
The indication of Cyramza (ramucirumab; Eli Lilly), in combination with FOLFIRI (irinotecan, folinic acid, and 5‑fluorouracil), has been extended to include the treatment of adult patients with metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin and a fluoropyrimidine. In addition, Cyramza in combination with docetaxel is also indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with disease progression after platinum-based chemotherapy. Cyramza is already indicated for the treatment of certain gastric and gastro-oesophageal cancers.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2016.20200699
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.Visit rpharms.com